Quantum dot-based multispectral fluorescent imaging to quantitatively study co-expressions of Ki67 and HER2 in breast cancer
Authors:
Open Access
- 1 August 2015
- journal article
- Published by Elsevier in Experimental and Molecular Pathology
- Vol. 99 (1) , 133-138
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81230031/H18)
- Hubei Province's Outstanding Medical Academic Leader Program (2013[4])
This publication has 36 references indexed in Scilit:
- Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registryBreast Cancer Research and Treatment, 2013
- Long-Term Prognostic Performance of Ki67 Rate in Early Stage, pT1-pT2, pN0, Invasive Breast CarcinomaPLOS ONE, 2013
- Cancer incidence and mortality in China, 2007Chinese Journal of Cancer Research, 2012
- Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working GroupJNCI: Journal of the National Cancer Institute, 2011
- Co-evolution of cancer microenvironment reveals distinctive patterns of gastric cancer invasion: laboratory evidence and clinical significanceJournal of Translational Medicine, 2010
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast CancerJournal of Clinical Oncology, 2010
- Ki67 in breast cancer: prognostic and predictive potentialThe Lancet Oncology, 2010
- The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapiesExperimental and Molecular Pathology, 2009
- Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009Annals of Oncology, 2009
- The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized MedicineThe Oncologist, 2009